The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).

This disclosure relates to nanoparticles for preventing, treating and reversing atherosclerosis.

Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intramuscular, intravenous, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The present disclosure, in particular, relates to RNA particles comprising RNA, at least one cationic or cationically ionizable lipid or lipid-like material, and at least one cationic polymer, wherein the particles do not have a core-shell structure.

Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).

We have developed novel shear-thinning biomaterials using silica nanoparticles, gelatin-based polymers and polypeptides such as anti-PD-1 antibodies. Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up.

A composition, and method for a targeted drug delivery is disclosed in treating central nervous system injury, including blast hearing loss, traumatic brain injury (TBI) and the like, by administering a subject with nanoparticle-based minocycline formulations. The formulation contains nanoparticles encapsulating minocycline for neuroprotective effect in TBI. Albumin nanoparticle-based minocycline formulations provide enhanced delivery to brain, and reduced toxicity at minimal dosage for treating a subject suffering from central nervous system injury including blast induced traumatic brain injury (bTBI). Nanoparticle administered at minimal dose in rat blast TBI model crossed blood-brain barrier (BBB) and enhanced therapeutic concentration compared to free minocycline. Provided is an effective and safe minocycline delivery in TBI with minimal or no toxicity for neuroprotective therapy. Studies indicate performance for behavioral (acute and chronic), pathological (chronic) and hearing loss mitigation using the disclosed drug and nanoparticles in rat moderate bTBI model.

Disclosed are a lymphoma cell-specific drug delivery system for the prevention or treatment of lymphoma and a production method therefor. The lymphoma cell-specific drug delivery system may be delivered into lymphoma cells in an improved manner compared to conventional single-target drug delivery systems, and is applicable to the delivery of various therapeutic drugs for the treatment of lymphoma through the application of a wide range of drugs and the same antibody functionalization strategy on the surface of different types of nanoparticles. In addition, the drug delivery system may be introduced into lymphoma as well as other cancer types by adjusting the type and mixing ratio of antibody, and may propose a method of introducing polymeric nucleic acid drugs having superior physiological stability and drug efficacy compared to conventional monomeric nucleic acid drugs, thereby enabling effective drug treatment of lymphoma which is highly resistant to intracellular drug delivery.

The invention relates to a lipoprotein cage for intracellular delivery of cargo, said lipoprotein cage comprises (i) a protein cage comprising at least one polypeptide comprising an amino acid sequence I consisting of SEQ ID NO: 1, wherein said protein cage possesses a positively charged interior; and (ii) a surfactant composition comprising one or more amphiphiles, wherein the one or more amphiphiles are selected such that the net charge of the composition is negative, wherein said surfactant composition is encapsulated into the assembled protein cage. The invention further relates to complex comprising the lipoprotein cage of the invention and one or more cargo molecules, and to a method for manufacturing the lipoprotein cage of the invention comprising the steps of self-assembling of a protein cage from at least one polypeptide comprising an amino acid sequence I, preferably from 24 polypeptides each comprising he amino acid sequence I, and encapsulating the anionic amphiphile of the invention into the protein cage, without disassembly of the protein cage.

An aluminum nanoparticle adjuvant carrier system with stabilizing surface coatings that can efficiently deliver protein or nucleic acid antigen payloads to naive, resident APCs is disclosed.